Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing

Israel Medical Association Journal

Volumn 6, Issue 10, 2004, Pages 610-618

  Belkic, Karen ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Early detection; Magnetic resonance spectroscopy; Mammography; Signal processing

Indexed keywords

CARBON 13; FLUORODEOXYGLUCOSE; GLYCEROPHOSPHORYLCHOLINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PHOSPHOETHANOLAMINE; PHOSPHORUS 31;

BREAST CANCER; CANCER SCREENING; CARBON NUCLEAR MAGNETIC RESONANCE; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; FOURIER TRANSFORMATION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; ISRAEL; MATHEMATICAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCINTIMAMMOGRAPHY; SIGNAL NOISE RATIO; SIGNAL PROCESSING;

BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MAMMOGRAPHY; MASS SCREENING; MATHEMATICS; PREDICTIVE VALUE OF TESTS; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 5044232263     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Adami H-O, Hunter D, Trichopoulos D. Textbook of Cancer Epidemiology. New York: Oxford University Press, 2002.
2. Allweis TM, Nissan A, Spira RM, Sklair-Levy M, Fruend HR, Peretz T. Screening mammography for early diagnosis of breast cancer: facts, controversies, and the implementation in Israel. Harefuah 2003;142:281-6, 317 (Hebrew).
3. Dagan E, Gershoni-Baruch R. Hereditary breast/ovarian cancer - pitfalls in genetic counselling. Clin Genet 2001;60:310-13.
4. Surbone A. Ethical implications of genetic testing for breast cancer susceptibility. Crit Rev Oncol Hematol 2001;40:149-57.
5. Nir-Caein R, Nahum R, Yogev Y, Rosenfeld J, Fisher M, Kaplan B. Ethnicity and attitude toward menopause and hormone replacement therapy in northern Israel. Clin Exp Obstet Gynecol 2002;29:91-4.
6. Merom D, Ifrah A, Cohen-Manheim I, Chinich A, Green MS. Factors predicting current use of hormone replacement therapy among menopausal Jewish women in Israel. The National Women's Health Interview Survey, 1998, IMAJ 2002;4:671-6.
7. Chlebowski RT, Hendrix SL, Langer RD, et al., for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
8. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2001;53:141-69.
9. Terán L. Compliance with Mammography Screening Guidelines among Latinas: An Exploratory Study. PhD thesis. University of Southern California School of Medicine, Department of Preventive Medicine, 2004.
10. Lubish L, Greenberg S, Friger M, Shvartzman P. Breast cancer screening in two multicultural family practice teaching clinics. IMAJ 2001;3:579-83.
11. Ore L, Hagoel L, Shifroni G, Rennert G. Compliance with mammography screening in Israeli women: the impact of a pre-scheduled appointment and of the letter-style. Isr J Med Sci 1997;33:103-11.
12. Remennick L. "I have no time for potential troubles": Russian immigrant women and breast cancer screening in Israel. J Immigr Health 2003;5:153-63.
13. Bastani R, Marcus AC, Maxwell AE, Das IP, Yan KX. Evaluation of an intervention to increase mammography screening in Los Angeles, Prev Med 1994;23:83-90.
14. Beemsterboer PM, Warmerdam PG, Boer R, de Koning HJ. Radiation risk of mammography related to benefit in screening programmes: a favorable balance? J Med Screen 1998;5:81-7.
15. Brenner DJ, Sawant SG, Hande MP, et al. Routine screening mammography: how important is the radiation-risk side of the benefit-risk equation? Int J Radiat Biol 2002;78:1065-7.
16. De Vita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2001.
17. Kuni H, Schmitz-Feuerhake I, Dieckmann H. Mammography screening - neglected aspects of radiation risks. Gesundheitswesen 2003;65:443-6.
18. Rosé C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002;23:613-18.
19. Prats E. Symposium of breast imaging. Nucl Med Commun 2002;23:607-8.
20. Kopans DB. Breast Imaging. 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1998.
21. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
22. Tabár L. Challenges in mammography from a clinical perspective [Abstract]. In: Imaging 2003: International Conference on Imaging Techniques in Subatomic Physics, Astrophysics, Medicine, Biology and Industry, 2003 June, Stockholm, Sweden.
23. Khalkhali I, Itti E. Functional breast imaging using the single photon technique. Nucl Med Commun 2002;23:609-11.
24. National Cancer Institute, Development of Novel Imaging Technologies (Phased Innovation Award), 2000 (http://www.health.gov/healthypeople/).
25. Jones T. The spectrum of medical imaging. Eur J Cancer 2002;38:2067-9.
26. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 2002;9:773-83.
27. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001;220:13-30.
28. Wiberg MK. Magnetic resonance imaging in breast diagnosis. PhD thesis. Karolinska Institute, Center for Surgical Sciences, Division of Radiology, 2002.
29. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions, J Natl Cancer Inst 2002;94:1197-203.
30. Belkić Dz. Fast Padé transform for magnetic resonance imaging and computerized tomography. Nucl Instr Meth Phys Res A 2001;471:165-9.
31. Belkić Dz. Exact analytical expressions for any Lorentzian spectrum in the fast Padé transform (FPT). J Comp Meth Sci Engin 2003;3:109-86.
32. Belkić Dz. Strikingly stable convergence of the Fast Padé Transform (FPT) for high-resolution parametric and non-parametric signal processing of Lorentzian and non-Lorentzian spectra Nucl Instr Meth Phys Res A 2004;525:366-71.
33. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer. Cancer Res 2002;62:1966-970.
34. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999;19:1737-46.
35. Belkić Dz. Strikingly stable convergence of the fast Padé transform: applications to magnetic resonance spectroscopy (MRS). J Comp Meth Sci Engin 2003;3:299-382.
36. Tkáč I, Andersen P Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo 1 H NMR spectroscopy of the human brain at 7 T. Magn Res Med 2001;46: 451-6.
37. Belkić K. The need for quantitative biomedical spectroscopic imaging through magnetic resonance in oncology beyond the conventional Fourier-based signal processing. J Comp Meth Sci Engin 2003; 3:535-61.
38. Belkić K. Magnetic resonance spectroscopic imaging in breast cancer detection: possibilities beyond the conventional theoretical framework for data analysis. Nucl Instr Meth Phys Res A 2004;525:313-21.
39. Cardenas K, Frisch K. Comprehensive breast cancer screening. Programs now include individual risk assessment. Postgrad Med 2003;113:34-46.
40. Hodgson SV, Heap E, Cameron J, et al. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet 1999;36:369-73.